Globus Medical, Inc. (GMED) Stock Forecast
Data as of Jul 31, 2026Healthcare · Current price $79.30 (-1.30%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 25, 2026 | Richard Newitter | Truist Financial | $115.00 | +45.0% |
| Jan 8, 2026 | Matt O'Brien | Piper Sandler | $115.00 | +45.0% |
| Dec 17, 2025 | Shagun Singh | RBC Capital | $100.00 | +26.1% |
| Dec 17, 2025 | Caitlin Cronin | Canaccord Genuity | $105.00 | +32.4% |
| Oct 28, 2025 | Thomas Stephan | Stifel Nicolaus | $64.00 | -19.3% |
| Dec 2, 2024 | Kallum Titchmarsh | Morgan Stanley | $100.00 | +26.1% |
| Aug 28, 2024 | Ryan Zimmerman | BTIG | $77.00 | -2.9% |
| Aug 7, 2024 | Vik Chopra | Wells Fargo | $78.00 | -1.6% |
| Jul 15, 2024 | Drew Ranieri | Morgan Stanley | $71.00 | -10.5% |
| May 29, 2024 | Ryan Zimmerman | BTIG | $72.00 | -9.2% |
| May 20, 2024 | Matt O'Brien | Piper Sandler | $80.00 | +0.9% |
| Mar 18, 2024 | Ryan Zimmerman | BTIG | $60.00 | -24.3% |
| Sep 19, 2023 | Mathew Blackman | Stifel Nicolaus | $61.00 | -23.1% |
| Dec 13, 2021 | Craig Bijou | Bank of America Securities | $80.00 | +0.9% |
| Aug 5, 2021 | Kyle Rose | Canaccord Genuity | $90.00 | +13.5% |
| Aug 5, 2021 | Matthew Henriksson | Citigroup | $93.00 | +17.3% |
| Aug 5, 2021 | Richard Newitter | Leerink Partners | $96.00 | +21.1% |
| May 5, 2021 | Steven Lichtman | Oppenheimer | $79.00 | -0.4% |
Top Analysts Covering GMED
GMED vs Sector & Market
| Metric | GMED | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.10 | 2.25 | 2.42 |
| Analyst Count | 10 | 8 | 19 |
| Target Upside | +33.1% | +16366.1% | +18.0% |
| P/E Ratio | 18.53 | 2.99 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $793M | $804M | $819M | 4 |
| 2026-12-31 | $3.18B | $3.20B | $3.23B | 10 |
| 2027-03-31 | $775M | $786M | $801M | 4 |
| 2027-06-30 | $828M | $840M | $856M | 4 |
| 2027-09-30 | $842M | $854M | $870M | 5 |
| 2027-12-31 | $903M | $916M | $933M | 4 |
| 2028-03-31 | $809M | $821M | $836M | 3 |
| 2028-06-30 | $861M | $874M | $890M | 3 |
| 2028-09-30 | $904M | $917M | $934M | 5 |
| 2028-12-31 | $956M | $970M | $988M | 3 |
| 2029-12-31 | $3.93B | $3.96B | $3.99B | 3 |
| 2030-12-31 | $4.21B | $4.24B | $4.27B | 6 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $1.14 | $1.16 | $1.19 | 3 |
| 2026-12-31 | $4.43 | $4.47 | $4.53 | 7 |
| 2027-03-31 | $1.08 | $1.10 | $1.12 | 3 |
| 2027-06-30 | $1.18 | $1.20 | $1.23 | 5 |
| 2027-09-30 | $1.23 | $1.25 | $1.28 | 3 |
| 2027-12-31 | $1.38 | $1.40 | $1.44 | 6 |
| 2028-03-31 | $1.09 | $1.11 | $1.14 | 4 |
| 2028-06-30 | $1.23 | $1.25 | $1.28 | 6 |
| 2028-09-30 | $1.35 | $1.37 | $1.41 | 4 |
| 2028-12-31 | $1.51 | $1.54 | $1.58 | 7 |
| 2029-12-31 | $6.24 | $6.29 | $6.36 | 1 |
| 2030-12-31 | $6.94 | $7.00 | $7.07 | 1 |
Frequently Asked Questions
What is the analyst consensus for GMED?
The consensus among 10 analysts covering Globus Medical, Inc. (GMED) is Buy with an average price target of $109.50.
What is the highest price target for GMED?
The highest price target for GMED is $115.00, set by Richard Newitter at Truist Financial on 2026-02-25.
What is the lowest price target for GMED?
The lowest price target for GMED is $60.00, set by Ryan Zimmerman at BTIG on 2024-03-18.
How many analysts cover GMED?
10 analysts have issued ratings for Globus Medical, Inc. in the past 12 months.
Is GMED a buy or sell right now?
Based on 10 analyst ratings, GMED has a consensus rating of Buy (2.10/5) with a +33.1% upside to the consensus target of $109.50.
What are the earnings estimates for GMED?
Analysts estimate GMED will report EPS of $1.16 for the period ending 2026-09-30, with revenue estimated at $804M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.